Lynx Therapeutics

Mar 24, 2000

Premium

Ž Lynx Therapeutics of Hayward

, Calif., has filed for a public offering of 1.5 million shares of common stock. It develops and applies technology for discovering gene expression patterns and genomic variations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Retirement Moves

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura Dies

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

This Week in PLOS

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Shuffle at IBM Watson Health

Stat News reports that the head of IBM Watson Health is leaving her post.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu